Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. oncomechaml

ONCOMECHAML SIGNED

Common Oncogenic Mechanisms in Multi-Partner Translocation Families in Acute Myeloid Leukemia

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 ONCOMECHAML project word cloud

Explore the words cloud of the ONCOMECHAML project. It provides you a very rough idea of what is the project "ONCOMECHAML" about.

gene    myeloid    blood    model    strategies    translocation    expression    driver    pipeline    pooled    mll    validated    aml    diagnosis    translocations    architecture    oncogenes    fused    networks    mechanisms    mortality    conserved    found    hypothesize    straightforward    molecular    interaction    representative    chromosomal    nup98    clinical    oncogenic    contribution    characterization    loci    therapeutic    denominators    mouse    acute    aberrations    leukemia    unknown    interactomes    physical    basic    complexity    hits    encoded    despite    act    cancer    informative    majority    cellular    mpt    significance    80    diagnostic    genetic    generate    relevance    proteins    patients    critical    screens    gt    recurrently    genes    fusion    transforming    recipient    arising    decisions    mechanism    frequent    effectors    experimental    complicated    functional    protein    confidence    unclear    shrna    models    datasets    primary    families    modular    cells    clinically    transformation    delineate    runx1   

Project "ONCOMECHAML" data sheet

The following table provides information about the project.

Coordinator		 VETERINAERMEDIZINISCHE UNIVERSITAET WIEN 

Organization address
address: Veterinaerplatz 1
city: VIENNA
postcode: 1210
website: www.vetmeduni.ac.at

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Austria [AT]
 Total cost 1˙499˙500 €
 EC max contribution 1˙499˙500 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2014-STG
 Funding Scheme ERC-STG
 Starting year 2015
 Duration (year-month-day) from 2015-06-01   to  2020-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    VETERINAERMEDIZINISCHE UNIVERSITAET WIEN AT (VIENNA) coordinator 513˙990.00
2    LUDWIG BOLTZMANN GESELLSCHAFT GMBH AT (WIEN) participant 985˙509.00

Map

 Project objective

Acute Myeloid Leukemia (AML) is the most frequent cancer of the blood system, with >80% mortality within 5 years of diagnosis. Straightforward clinical decisions are complicated by the genetic complexity of AML. In particular, fusion proteins arising from chromosomal aberrations are recurrently found in AML and often act as strong driver oncogenes. In “Multi-Partner Translocation” (MPT) families, one specific gene is fused to many recipient loci. Due to this modular architecture, MPT families are of particular interest to comparative studies of oncogenic mechanisms. The three most common MPT families in AML represent translocations of the MLL, RUNX1 and NUP98 genes. Despite their clinical significance, the molecular mechanism of transformation remains unknown for the majority of fusion proteins and it is unclear if transforming mechanisms are conserved within and across different MPT families. We hypothesize that common oncogenic mechanisms of fusion proteins are encoded in physical and genetic cellular interaction networks that are specific to MPT families. We propose to delineate critical common effectors of oncogenic mechanisms in AML driven by MPT families through a comprehensive, comparative, functional analysis of 20 clinically representative MLL-, RUNX1- and NUP98-fusion proteins using a unique experimental pipeline. Characterization of protein interactomes and their effects on gene expression will identify common cellular denominators of MPT families, whose functional contribution will be assessed through pooled shRNA screens in clinically relevant model systems. High-confidence hits will be validated in mouse models and primary cells from AML patients. This project will generate large informative datasets and novel experimental systems that are of relevance for basic and clinical cancer research. It will contribute to improved understanding of oncogenic mechanisms, which may directly impact on diagnostic and therapeutic strategies in the management of AML.

 Publications

year authors and title journal last update
List of publications.
2016 Thomas Eder, Florian Grebien, Thomas Rattei
NVT: a fast and simple tool for the assessment of RNA-seq normalization strategies
published pages: btw521, ISSN: 1367-4803, DOI: 10.1093/bioinformatics/btw521 		Bioinformatics 2019-05-27
2017 Katrin Noack, Nisintha Mahendrarajah, Dorle Hennig, Luisa Schmidt, Florian Grebien, Dagmar Hildebrand, Markus Christmann, Bernd Kaina, Andreas Sellmer, Siavosh Mahboobi, Katharina Kubatzky, Thorsten Heinzel, Oliver H. Krämer
Analysis of the interplay between all-trans retinoic acid and histone deacetylase inhibitors in leukemic cells
published pages: 2191-2208, ISSN: 0340-5761, DOI: 10.1007/s00204-016-1878-5 		Archives of Toxicology 91/5 2019-05-27
2016 Tahereh Javaheri, Zahra Kazemi, Jan Pencik, Ha TT Pham, Maximilian Kauer, Rahil Noorizadeh, Barbara Sax, Harini Nivarthi, Michaela Schlederer, Barbara Maurer, Maximillian Hofbauer, Dave NT Aryee, Marc Wiedner, Eleni M Tomazou, Malcolm Logan, Christine Hartmann, Jan P Tuckermann, Lukas Kenner, Mario Mikula, Helmut Dolznig, Aykut Üren, Günther H Richter, Florian Grebien, Heinrich Kovar, Richard Moriggl
Increased survival and cell cycle progression pathways are required for EWS/FLI1-induced malignant transformation
published pages: e2419, ISSN: 2041-4889, DOI: 10.1038/cddis.2016.268 		Cell Death and Disease 7/10 2019-05-27
2016 Jan Pencik, Ha Thi Thanh Pham, Johannes Schmoellerl, Tahereh Javaheri, Michaela Schlederer, Zoran Culig, Olaf Merkel, Richard Moriggl, Florian Grebien, Lukas Kenner
JAK-STAT signaling in cancer: From cytokines to non-coding genome
published pages: 26-36, ISSN: 1043-4666, DOI: 10.1016/j.cyto.2016.06.017 		Cytokine 87 2019-05-27
2018 Ha Thi Thanh Pham, Barbara Maurer, Michaela Prchal-Murphy, Reinhard Grausenburger, Eva Grundschober, Tahereh Javaheri, Harini Nivarthi, Auke Boersma, Thomas Kolbe, Mohamed Elabd, Florian Halbritter, Jan Pencik, Zahra Kazemi, Florian Grebien, Markus Hengstschläger, Lukas Kenner, Stefan Kubicek, Matthias Farlik, Christoph Bock, Peter Valent, Mathias Müller, Thomas Rülicke, Veronika Sexl, Richard Moriggl
STAT5BN642H is a driver mutation for T cell neoplasia
published pages: 387-401, ISSN: 0021-9738, DOI: 10.1172/JCI94509 		Journal of Clinical Investigation 128/1 2019-05-27

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ONCOMECHAML" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ONCOMECHAML" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

AST (2019)

Automatic System Testing

Read More  

ERC VP CSA (2018)

Support to the Vice-Presidents of the ERC Scientific Council 2018

Read More  

CURVE-X (2019)

Industrialisation of curved sensors and related imagers

Read More